CMS and FDA RAPID Coverage Pathway 2026 for Breakthrough Medical Devices

On 23 April 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced the RAPID Coverage Pathway, a new coordinated framework designed to accelerate Medicare coverage for certain breakthrough medical devices. The initiative aims to reduce delays between FDA market authorization and Medicare national coverage decisions, improving patient access to innovative technologies.

What Is the RAPID Coverage Pathway?

The RAPID (Regulatory Alignment for Predictable and Immediate Device) coverage pathway is a joint CMS–FDA initiative that integrates regulatory review and coverage planning earlier in the device development process.

Key Concept of the Pathway

The pathway enables:

• Early alignment between FDA and CMS on evidence requirements  

• Joint engagement with medical device innovators  

• Use of shared clinical evidence for both regulatory approval and coverage decisions  

This coordinated approach aims to eliminate duplication and reduce delays in market access.

How the RAPID Pathway Works

Traditionally, Medicare coverage decisions often occur long after FDA authorization. The RAPID pathway changes this by aligning timelines and expectations earlier.

Early Evidence Alignment

Manufacturers work with CMS and FDA during development to ensure:

• Clinical endpoints are relevant for Medicare populations  

• Evidence generated for FDA review also supports coverage decisions  

• Study design meets both regulatory and reimbursement requirements  

This reduces the need for additional post-approval evidence collection.

Simultaneous Regulatory and Coverage Action

Under the RAPID pathway:

• CMS issues a proposed National Coverage Determination (NCD) on the same day FDA grants market authorization  

• A statutory 30-day public comment period follows  

• Final coverage decisions can occur significantly faster than traditional processes  

This coordinated timing improves predictability for manufacturers and clinicians.

Eligibility Criteria for RAPID Coverage Pathway

Not all devices qualify. The pathway is limited to specific high-impact technologies.

Eligible Devices Include:

• FDA-designated Breakthrough Devices addressing unmet medical needs in Medicare populations  

• Certain Class II devices participating in the FDA Total Product Life Cycle Advisory Program (TAP)  

• Class III devices, regardless of TAP participation  

Study Requirements:

To qualify, devices must:

• Be under an Investigational Device Exemption (IDE) study  

• Enroll Medicare beneficiaries  

• Evaluate clinical outcomes agreed upon by CMS and FDA  

Expected Impact on Market Access

The RAPID pathway is designed to significantly reduce time to coverage and improve access to innovation.

Key Benefits Include:

• Faster Medicare coverage decisions (potentially within ~2 months post-approval)  

• Reduced gap between FDA approval and reimbursement  

• Improved alignment between clinical evidence and payer expectations  

• Greater transparency in coverage requirements for innovators  

Under current processes, coverage decisions can take a year or longer, making this a major procedural acceleration.

Implications for Manufacturers and Innovators

The RAPID pathway introduces a shift in how evidence planning should be approached.

Manufacturers should now:

• Engage CMS earlier in clinical development  

• Align IDE study endpoints with reimbursement needs  

• Incorporate payer requirements into trial design  

• Participate in FDA TAP where applicable  

• Plan for simultaneous regulatory and coverage strategies  

Early coordination becomes a critical success factor.

Regulatory Significance

This initiative represents a deeper integration of regulatory approval and reimbursement frameworks in the U.S. healthcare system. It reflects a broader trend toward:

• Value-based healthcare decision-making  

• Evidence harmonization across agencies  

• Faster patient access to breakthrough technologies  

• Reduced administrative duplication for innovators  

Internal Resource

FDA US Medical Device Registration

External Resource

FDA Official Announcement

‍